← Back to ProjectsConcept
Project 006

Medical Systems — Upstream Diagnosis Before Irreversibility

Irreversibility Progression

  1. 1
    Concept
    Define the non-negotiables. Specify what must never happen and the boundary conditions that refuse it.
    Phase gates (project-specific)
    • Identify hidden dynamics.
    • Define irreversible thresholds.
    • Select measurable proxies.
  2. 2
    Prototype
    Prove bounded failure. Demonstrate the refusal holds under representative stress and degradation.
    Phase gates (project-specific)
    • Validate early detection.
    • Correlate with outcomes.
    • Optimize clinical timing.
  3. 3
    Deployment
    Lock custody across time. Make irreversibility institutional: accountability and exit routes are fixed.
    Phase gates (project-specific)
    • Clinical integration.
    • Regulatory alignment.
    • Population-scale screening.

The timeline becomes real only when each gate is satisfied. Irreversibility is not a label; it is a completed constraint.

Fixed Irreversible Condition

Diagnosis must expose latent dynamics before irreversible pathology manifests.

Target Scale

Years5–15 years
Generations1 generation
CapitalClinical devices & validation

Irreversibility Lock Meter

Time Lock
5–15 years
Generational Lock
1 generation
Capital Lock
Clinical devices & validation
Phase Lock
Concept

As the project advances, the system moves from reversible choices to locked commitments. The meter visualizes where irreversibility is accumulating.

Reality Connection

What is fixed now

  • Focus on clearance, flow, transfer dynamics.
  • Shift diagnosis upstream in time.
  • Intervention windows fixed earlier.

Evidence artifacts

  • Diagnostic protocol concept
  • Physiological flow models
  • Clinical feasibility note

Phase gates

Concept
  • Identify hidden dynamics.
  • Define irreversible thresholds.
  • Select measurable proxies.
Prototype
  • Validate early detection.
  • Correlate with outcomes.
  • Optimize clinical timing.
Deployment
  • Clinical integration.
  • Regulatory alignment.
  • Population-scale screening.